Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.
about
Vascular Parkinsonism: deconstructing a syndrome.Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers.Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.Sigma-1 receptor chaperones in neurodegenerative and psychiatric disordersIncidence of dementia with Lewy bodies and Parkinson disease dementiaCombination therapies: The next logical Step for the treatment of synucleinopathies?Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathyFamilial aggregation of Parkinson disease in Utah: A population-based analysis using death certificates.Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity.AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study.Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease.Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update.Rational drug discovery design approaches for treating Parkinson's disease.ɑ-Synuclein strains and the variable pathologies of synucleinopathies.Time Trends in the Incidence of Parkinson Disease.Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010.Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study.Multiple system atrophy: experimental models and reality.Parkinson disease with and without Dementia: A prevalence study and future projections.Prevalence of and indications for antipsychotic use in Parkinson's disease.Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease.Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.Response to Letter by Friedman on "Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study".Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.Inappropriate Medication Use in Hospitalized Patients Diagnosed with Parkinson's Disease
P2860
Q27333064-2E746EEF-E312-4079-8E89-6E994AD6755DQ30578913-CE228DCE-A566-4CA6-A6D9-F4188861BDD5Q33456273-8D26C3E4-432C-4311-821E-8D50C064242AQ33865366-41CCC0B3-82D4-4EEB-B3D5-B7D49D10B9ADQ33920251-32593120-60C9-43C0-BE73-7CBD892ED076Q34275050-9DF7EA69-2C3A-4497-9899-1582AECB0032Q36563062-D4213A6E-5BF6-4388-8EB9-564EB9A0999CQ36672116-AB4A7D95-5FB8-400D-B0CB-462B75CDCDF6Q36794110-F51AB69D-86E5-4438-BAB3-59C9DD8A576BQ36885365-2188B994-E68D-4B26-8E9C-561DE89117B6Q37533514-E4A1D1A7-62D3-4F43-B608-60C836B6E6FBQ37633577-6C0D5634-1AA1-465C-B9E2-9D48A092FD0BQ37653322-DD52B139-EE90-439A-8947-1EF8B8B20482Q38187007-6C3825A3-8BE2-4D5C-BF98-561BBDDB0903Q38343049-BBEB3870-3BD0-456D-A1E1-3BF80E3BBF3CQ38392505-9A2E8827-5A28-491F-AE9B-14E5987F2F42Q38520864-1A6F81C7-3EAC-490F-A8FA-3BB62A763BE4Q38753941-CE7F385F-91C6-456B-BB0A-5B79FC0C06F4Q38870766-EB8345C1-9638-4DAA-BCC8-350612E76917Q40069625-1A12D36F-E343-4954-B1D9-E5228590BB87Q40201095-3A39712B-F5D8-4A5A-B837-D135D4F918C1Q46726761-8333D5A2-7AA1-4F8E-93BB-C58EDBD335A0Q47720092-9918FD95-7C03-4345-8029-D53141C39177Q48349028-064A71C9-EF94-44AE-A6A5-86158C73F756Q48762323-2A41877B-6648-4FFF-8A33-6D1BE1D75118Q49817768-0AC8B62E-70BC-4745-942A-E6D2AC7ED80FQ50585671-5E7D3B0D-E972-4355-A0DE-5AA1B607DF79Q50890383-1A355DD5-A9B6-4896-822F-51C1FE7B5AC2Q58736927-A4AAFCAD-FD7B-4214-B89B-A0E1D0789E8E
P2860
Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.
@en
Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.
@nl
type
label
Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.
@en
Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.
@nl
prefLabel
Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.
@en
Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.
@nl
P2093
P2860
P1433
P1476
Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.
@en
P2093
Brandon R Grossardt
James H Bower
Rodolfo Savica
Walter A Rocca
P2860
P304
P356
10.1001/JAMANEUROL.2013.114
P407
P577
2013-07-01T00:00:00Z